<p>马萨诸塞州剑桥 --（商业资讯）--Scholar Rock（纳斯达克代码：SRRK；以下简称 “公司”）今天宣布，公司向两名新聘员工授予了总计 7,800 股普通股的诱导性股权奖励，其中包括总计 4,457 股普通股的诱导性股票期权和总计 3,343 股普通股的诱导性限制性股票单位。</p>
<p>这些奖励受公司 2022 年诱导性股权计划（以下简称 “计划”）中规定的所有条款、条件和其他条款的约束。</p>
<p>该计划最初由公司董事会于 2022 年 6 月 16 日通过，并不时修订，专门用于向未曾是 Scholar Rock 员工的个人授予股权奖励，或在经过真实的非就业期后，作为诱导这些个人与 Scholar Rock 签订雇佣合同的重要条件，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>诱导性股票期权的行使价格为 45.25 美元，等于 Scholar Rock 普通股在 2025 年 12 月 8 日的收盘价。诱导性股票期权将在每位员工入职一周年时，归属与奖励相关的 25% 普通股，剩余的 75% 普通股将在此后以 12 个相等的季度分期归属。诱导性限制性股票单位的归属将分为四个相等的年度分期。所有与诱导性奖励相关的归属均需员工在适用的归属日期继续在公司服务。</p>
<p><strong>关于 Scholar Rock</strong></p>
<p>Scholar Rock 是一家处于后期阶段的生物制药公司，专注于为患有脊髓性肌萎缩症（SMA）及其他罕见、严重和致残的神经肌肉疾病的儿童和成人开发和商业化 apitegromab。作为肌肉生物学领域的全球领导者，该领域专注于调节肌肉质量的蛋白质，生物制药公司以学者岩石与蛋白质结构的视觉相似性命名。我们致力于解锁根本不同的治疗方法，依靠广泛应用的专有平台，该平台开发了新型单克隆抗体，以极高的选择性调节蛋白质生长因子。Scholar Rock 每天努力通过其高度创新的抗肌肉抑制素项目为患者创造新的可能性，包括在其他罕见神经肌肉疾病中的机会。了解更多信息，请访问 ScholarRock.com，并在 X 和 LinkedIn 上关注 @ScholarRock。</p>
<p>Scholar Rock®是 Scholar Rock, Inc.的注册商标。</p>
<p><strong>关于 Scholar Rock 的其他信息的可用性</strong></p>
<p>投资者和其他人应注意，我们通过公司网站 www.scholarrock.com 与投资者和公众沟通，包括但不限于公司披露、投资者演示文稿和常见问题解答、证券交易委员会的备案、新闻稿、公开电话会议记录和网络广播记录，以及在 X（前称 Twitter）和 LinkedIn 上的信息。我们在网站或 X（前称 Twitter）或 LinkedIn 上发布的信息可能被视为重要信息。因此，我们鼓励投资者、媒体和其他感兴趣的人定期查看我们发布的信息。我们网站或社交媒体的内容不应被视为纳入 1933 年证券法（经修订）下的任何备案。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2MDE0MDFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2MDE0MDFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212601401/en/</p>
<p><strong>Scholar Rock</strong></p>
<p><strong>投资者</strong></p>
<p>Laura Ekas, Ph.D.</p>
<p><strong>ir@scholarrock.com</strong></p>
<p>917-439-0374</p>
<p><strong>媒体</strong></p>
<p>Molly MacLeod</p>
<p><strong>media@scholarrock.com</strong></p>
<p>802-579-5995</p>
<p>来源：Scholar Rock</p>

SRRK

<p>Scholar Rock 宣布根据纳斯达克上市规则 5635(c)(4) 为两名新员工授予诱导性股权奖励，总计 7,800 股普通股。这些奖励包括股票期权和限制性股票单位，受公司 2022 年诱导性股权计划的约束。Scholar Rock 是一家专注于开发神经肌肉疾病治疗方案的生物制药公司</p>

<p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥 --（商业资讯）--Scholar Rock（纳斯达克代码：SRRK；以下简称 “公司”）今天宣布，公司向两名新聘员工授予了总计 7,800 股普通股的诱导性股权奖励，其中包括总计 4,457 股普通股的诱导性股票期权和总计 3,343 股普通股的诱导性限制性股票单位。</p>
</div><p>The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.</p>
<div class="lb-trans"><p>这些奖励受公司 2022 年诱导性股权计划（以下简称 “计划”）中规定的所有条款、条件和其他条款的约束。</p>
</div><p>The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>该计划最初由公司董事会于 2022 年 6 月 16 日通过，并不时修订，专门用于向未曾是 Scholar Rock 员工的个人授予股权奖励，或在经过真实的非就业期后，作为诱导这些个人与 Scholar Rock 签订雇佣合同的重要条件，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The inducement stock options have an exercise price of $45.25, which is equal to the closing price of Scholar Rock’s common stock on December 8, 2025. The inducement stock options will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of each employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 12 equal quarterly installments thereafter. Vesting for the inducement restricted stock units will be in four equal annual installments. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.</p>
<div class="lb-trans"><p>诱导性股票期权的行使价格为 45.25 美元，等于 Scholar Rock 普通股在 2025 年 12 月 8 日的收盘价。诱导性股票期权将在每位员工入职一周年时，归属与奖励相关的 25% 普通股，剩余的 75% 普通股将在此后以 12 个相等的季度分期归属。诱导性限制性股票单位的归属将分为四个相等的年度分期。所有与诱导性奖励相关的归属均需员工在适用的归属日期继续在公司服务。</p>
</div><p><strong>About Scholar Rock</strong></p>
<div class="lb-trans"><p><strong>关于 Scholar Rock</strong></p>
</div><p>Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.</p>
<div class="lb-trans"><p>Scholar Rock 是一家处于后期阶段的生物制药公司，专注于为患有脊髓性肌萎缩症（SMA）及其他罕见、严重和致残的神经肌肉疾病的儿童和成人开发和商业化 apitegromab。作为肌肉生物学领域的全球领导者，该领域专注于调节肌肉质量的蛋白质，生物制药公司以学者岩石与蛋白质结构的视觉相似性命名。我们致力于解锁根本不同的治疗方法，依靠广泛应用的专有平台，该平台开发了新型单克隆抗体，以极高的选择性调节蛋白质生长因子。Scholar Rock 每天努力通过其高度创新的抗肌肉抑制素项目为患者创造新的可能性，包括在其他罕见神经肌肉疾病中的机会。了解更多信息，请访问 ScholarRock.com，并在 X 和 LinkedIn 上关注 @ScholarRock。</p>
</div><p>Scholar Rock® is a registered trademark of Scholar Rock, Inc.</p>
<div class="lb-trans"><p>Scholar Rock®是 Scholar Rock, Inc.的注册商标。</p>
</div><p><strong>Availability of Other Information About Scholar Rock</strong></p>
<div class="lb-trans"><p><strong>关于 Scholar Rock 的其他信息的可用性</strong></p>
</div><p>Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</p>
<div class="lb-trans"><p>投资者和其他人应注意，我们通过公司网站 www.scholarrock.com 与投资者和公众沟通，包括但不限于公司披露、投资者演示文稿和常见问题解答、证券交易委员会的备案、新闻稿、公开电话会议记录和网络广播记录，以及在 X（前称 Twitter）和 LinkedIn 上的信息。我们在网站或 X（前称 Twitter）或 LinkedIn 上发布的信息可能被视为重要信息。因此，我们鼓励投资者、媒体和其他感兴趣的人定期查看我们发布的信息。我们网站或社交媒体的内容不应被视为纳入 1933 年证券法（经修订）下的任何备案。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2MDE0MDFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251212601401r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251212601401/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212601401/en/</p>
</div><p><strong>Scholar Rock</strong></p>
<div class="lb-trans"><p><strong>Scholar Rock</strong></p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Laura Ekas, Ph.D.</p>
<div class="lb-trans"><p>Laura Ekas, Ph.D.</p>
</div><p><strong>ir@scholarrock.com</strong></p>
<div class="lb-trans"><p><strong>ir@scholarrock.com</strong></p>
</div><p>917-439-0374</p>
<div class="lb-trans"><p>917-439-0374</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒体</strong></p>
</div><p>Molly MacLeod</p>
<div class="lb-trans"><p>Molly MacLeod</p>
</div><p><strong>media@scholarrock.com</strong></p>
<div class="lb-trans"><p><strong>media@scholarrock.com</strong></p>
</div><p>802-579-5995</p>
<div class="lb-trans"><p>802-579-5995</p>
</div><p>Source: Scholar Rock</p>
<div class="lb-trans"><p>来源：Scholar Rock</p>
</div>

Scholar Rock 根据纳斯达克上市规则 5635(c)(4) 报告新的员工激励授予 | SRRK 股票新闻